

Acknowledgement

First, thanks to Allah, the most compassionate and most merciful as we feel his great care, support and guidance in every step in our life.

I wish to express my most sincere; heart felt appreciation and deep thanks to:

Prof. Dr. Mohamed Osman Azzazi, professeur of internal medicine and hematology –faculty of medicine- Ain Shams University. For generous supervision, valuable instruction, careful reading, beneficial remarks and unlimited encouragement throughout the whole work.

I would like to express my sincere thank and deep appreciation to:

Prof. Dr. Hani Mohamed Abd Allah Hegab, assistant professeur of internal medicine and hematology –faculty of medicine- Ain Shams University. For his support, encouragement, cooperation and his devoted time and effort in this study.

And finally, I wish to express my special thanks and consideration to:

Dr. Gihan Mohamed Kamal, lecturer of internal medicine and hematology –faculty of medicine- Ain Shams University. For her valuable comments and support during the preparation of the study.

List of contents

• List of tables.....	1
• List of figures.....	2
• List of abbreviations.....	3
• Introduction.....	6
• Helicobacter pylori:	
▪ History.....	9
▪ Epidemiology.....	11
▪ Microbiology.....	13
▪ Genome Study.....	15
▪ Pathophysiology.....	17
• Anti-bacterial Properties of Human Stomach.....	22
• Immune response to Helicobacter pylori infection.....	25
• Factors Modulating the Immune Response to H. pylori in Humans.....	30
• Diagnosis.....	33

• Treatment.....	34
• Prevention.....	36
• Prognosis.....	38
• Lymphoma:	
▪ About Lymphoma.....	40
▪ WHO classification of lymphoma.....	43
• Gastric Lymphoma	
▪ Epidemiology.....	45
▪ General Histological and Immunophenotypic Characteristics.....	47
▪ Diagnosis & staging.....	49
• Types of Gastric Lymphoma:	
▪ Gastric MALT lymphoma.....	53
▪ Diffuse large B cell lymphoma.....	66
▪ Follicular lymphoma.....	72
▪ Mantle cell lymphoma.....	78

▪ Peripheral T cell lymphoma.....	80
▪ Hodgkin's lymphoma.....	83
• Role of Surgery in Primary Gastric Lymphoma.....	87
• Targeted Treatment of Lymphoma:	
▪ About target therapies.....	90
▪ Targeted monoclonal antibodies.....	91
▪ TNF receptors superfamily members.....	96
▪ Antibody-drug conjugates.....	100
▪ Molecules targeting oncogenic pathways.....	104
▪ Other promising agents in development.....	116
▪ Challenges and future directions.....	119
▪ Conclusion.....	128
• References.....	129

GASTRIC LYMPHOMA

HELICOBACTER PYLORI

INTRODUCTION

List of contents

• List of tables -----	1
• List of figures -----	2
• List of abbreviations -----	3
• Introduction -----	6
• Helicobacter pylori:	
▪ History -----	9
▪ Epidemiology -----	11
▪ Microbiology -----	13
▪ Genome Study -----	15
▪ Pathophysiology -----	17
• Anti-bacterial Properties of Human Stomach -----	22
• Immune response to Helicobacter pylori infection -----	25
• Factors Modulating the Immune Response to H. pylori in Humans -----	30
• Diagnosis -----	33
• Treatment -----	34
• Prevention -----	36
• Prognosis -----	38
• Lymphoma:	
▪ About Lymphoma -----	40

▪ WHO classification of lymphoma -----	43
• Gastric Lymphoma	
▪ Epidemiology -----	45
▪ General Histological and Immunophenotypic Characteristics -----	47
▪ Diagnosis & staging -----	49
• Types of Gastric Lymphoma:	
▪ Gastric MALT lymphoma -----	53
▪ Diffuse large B cell lymphoma -----	66
▪ Follicular lymphoma -----	72
▪ Mantle cell lymphoma -----	78
▪ Peripheral T cell lymphoma -----	80
▪ Hodgkin's lymphoma -----	83
• Role of Surgery in Primary Gastric Lymphoma -----	87
• Targeted Treatment of Lymphoma:	
▪ About target therapies -----	90
▪ Targeted monoclonal antibodies -----	91
▪ TNF receptors superfamily members -----	96
▪ Antibody-drug conjugates -----	100
▪ Molecules targeting oncogenic pathways ----	104
▪ Other promising agents in development -----	116
▪ Challenges and future directions -----	119
▪ Conclusion -----	128
• References -----	129

LYMPHOMA

List of Tables:

- (Table 1): ----- 31
- (Table 2): ----- 48
- (Table 3): ----- 52
- (Table 4): ----- 93
- (Table 5): ----- 98
- (Table 6): ----- 109
- (Table 7): ----- 124

List of figures:

- (Figure 1): ----- 14
- (Figure 2): ----- 23
- (Figure 3): ----- 104
- (Figure 4): ----- 106
- (Figure 5): ----- 119

List of Abbrerreviations:

Cag: Cytotoxin-associated gene.

CD: Cluster of differentiation.

Nod1: Nucleotide-biding oligomerization domain-containing protein 1.

EGFR: Epidermal growth factor receptor.

TNF- α : Tumor necrosis factor-alpha.

IL-6: Interleukin-6.

FOXP3: Forkhead box P3 is a protein involved in immune system responses.

Th1: T helper cell 1.

IFN- γ : Interferon gamma.

Ig: Immunoglobulin.

CLO test: Campylobacter-like organism test.

ELIZA: Enzyme-linked immunosorbent assay.

HP-NAP: Helicobacter pylori neutrophil activating protein.

HspA: Heat shock protein A.

MALT: Mucosa-associated lymphoid tissue.

FISH: Fluorescence in situ hybridization.

PET: Positron emission tomography.

NF- κ B: Nuclear factor kappa B.

CR: Complete remission.

PCR: Polymerase chain reaction.

Gy: Gray.

OS: Overall survival.

PFS: Progression-free survival.

DFS: Disease-free survival.

RT: Radiotherapy.

PR: Partial Response.

EFS: Event-free survival.

ASCO: American Society of Clinical Oncology.

NCCN: National Comprehensive Cancer Network.

DNA: Deoxyribonucleic acid.

FDA: Food and Drug Administration.

mAB: Monoclonal antibody.

ORR: Overall response rate.

TRAIL: TNF-related apoptosis-inducing ligand.

ADC: Anti-drug conjugate.

HDACs: Histone deacetylases.

mTOR: Mammalian target of rapamycin.

DLTs: Dose-limiting toxic effects.

ERK: Extracellular signal-regulated kinase.

RANK: Receptor activator for NK-kB.

BAFF: B-cell activating factor.

JAK/STAT: Janus kinase/signal transducer and activator of transcription.

ATP: Adenosine triphosphate.

Akt: Known as protein kinase B.

GSK-3B: Glycogen synthase kinase 3 beta.

Syk: Spleen tyrosine kinase.

RECIST: Response Evaluation Criteria In Solid Tumors.